Skip to main content

Table 3 Summary of EQ-5D questionnaire by dimension

From: Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

 

Idelalisib/rituximab/bendamustine, N = 207

Placebo/rituximab/bendamustine, N = 209

Dimensions

Baseline

Week 24

Week 48

Baseline

Week 24

Week 48

Anxiety/Depression

 Level 1

113 (57.1)

102 (65.8)

85 (66.4)

117 (59.1)

91 (60.3)

70 (66.7)

 Level 2

84 (42.4)

50 (32.3)

41 (32.0)

75 (37.9)

55 (36.4)

32 (30.5)

 Level 3

1 (0.5)

3 (1.9)

2 (1.6)

6 (3.0)

5 (3.3)

3 (2.9)

Mobility

 Level 1

145 (73.6)

119 (76.8)

94 (73.4)

142 (71.4)

112 (74.7)

84 (80.0)

 Level 2

52 (26.4)

36 (23.2)

34 (26.6)

55 (27.6)

38 (25.3)

21 (20.0)

 Level 3

0

0

0

2 (1.0)

0

0

Pain/Discomfort

 Level 1

105 (53.3)

96 (61.9)

77 (60.2)

114 (57.0)

79 (52.3)

63 (60.6)

 Level 2

85 (43.1)

54 (34.8)

51 (39.8)

81 (40.5)

69 (45.7)

37 (35.6)

 Level 3

7 (3.6)

5 (3.2)

0

5 (2.5)

3 (2.0)

4 (3.8)

Self-Care

 Level 1

184 (92.9)

136 (87.7)

115 (89.8)

184 (92.5)

131 (86.8)

92 (87.6)

 Level 2

14 (7.1)

19 (12.3)

13 (10.2)

13 (6.5)

20 (13.2)

12 (11.4)

 Level 3

0

0

0

2 (1.0)

0

1 (1.0)

Usual Activities

 Level 1

126 (63.6)

93 (60.4)

83 (64.8)

122 (61.3)

87 (57.6)

71 (68.3)

 Level 2

65 (32.8)

52 (33.8)

45 (35.2)

70 (35.2)

61 (40.4)

31 (29.8)

 Level 3

7 (3.5)

9 (5.8)

0

7 (3.5)

3 (2.0)

2 (1.9)

  1. Analyzed in the ITT population. All data represented as n (%)
  2. Level 1: no problems; Level 2: some problems; Level 3: extreme problems
  3. EQ-5D EuroQoL Five-Dimension, ITT intent-to-treat